🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
92.49
+0.54 (0.59%)
At close: Nov 18, 2026, 4:00 PM EST
92.60
+0.11 (0.12%)
After-hours: Nov 18, 2026, 4:32 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

Four approved medicines support FY 2026 revenue guidance of $715M–$720M, with cash flow positive status expected in 2027. Planned 2027 filings could lead to approvals and launches from late 2027 through 2028.

Peter Radovich
President and COO, Mirum

Hi, everyone. I'm Peter Radovich, President, Chief Operating Officer at Mirum, and I just want to thank you all in advance for taking time out of your conference schedule to come hear about Mirum. First, I just want to mention, I'll be making forward-looking statements, so for a full disclosure of our risk factors, I can refer you to our SEC filings on file with SEC. To give those of you an overview on Mirum who may not be familiar with us, Mirum's founding mission was to create a rare disease company that makes high-impact medicines for patients suffering from rare diseases. Often, we're focused in rare diseases that might be kind of underappreciated by other players in our industry that through focused grit, whether that be development, regulatory, or commercialization, we found that we can unlock a lot of value.

Mirum's only been around for eight years, and in eight years, I'm proud to say we have four approved medicines, that you see here on the page, and have grown the top line to be approaching three-quarters of a billion this year, so the guidance of $715 million-$720 million, with excellent growth trends from these four products into 2027, and two new product launches that'll come online primarily in 2028. Really excited about what this focused business model has delivered, both economically as well as for patients. We organize our portfolio into a rare liver business unit and a rare genetic disease business unit.

LIVMARLI was the flagship of the company, is our first FDA-approved product in 2021, has two approved indications, just recently had positive phase III data, and a third that I'll tell you more about, that we'll be filing a marketing application for next year. Really excited about that. Also in the rare liver portfolio, both volixibat and brelovitug reported positive pivotal data this year, and heading towards NDA and BLA submissions next year. Really excited about that. In our rare genetic disease business, CTEXLI CHOLBAM, legacy products, but our team has done an excellent job bending the curve with patient finding there, and just recently had ATEBRIOZ approved by the FDA and launched in October. Very excited about the progress we've had across the business. When you look in total, there's over $4 billion in peak sales potential inside of Mirum's portfolio today.

$3 billion in the liver portfolio, as well as meaningful opportunity in the rare genetic business. Just a word about our footprint. We have built a commercialization team, sales, marketing, access, medical affairs, supply chain, G&A support across both U.S., Canada, as well as Western and Central Europe, and have distributor and other partners that enable us to expand our reach and our impact on patients living with these diseases around the world. First, LIVMARLI, just to say a bit about LIVMARLI, is really a very strong growth product. Was originally approved in late 2021, September 2021, by FDA in its first indication. Its second indication, PFIC, was approved in 2025, and you can see here on the page, it was an excellent growth trajectory before the second indication came online, but really a nice inflection in 2025, 69% year-on-year growth rate.

This trend with the business has really continued into 2026. In fact, the LIVMARLI net product sales for the first three quarters of 2026 have already surpassed 2025. I will tell you more about the drivers of that on the next page here. The Alagille syndrome indication, original FDA approval, as I mentioned, in 2021, EMA and others shortly after that. About 2,000 addressable patients in the U.S. and Europe, about 1,000 in the U.S. LIVMARLI has a commanding market share in this space. North of 80% of patients receiving an IBAT are receiving LIVMARLI, and probably have penetrated about 50% of the addressable population. We still see new patient starts in Alagille syndrome every month, every quarter. Also see weight-based dose adjustments there. That is kind of the core base of the growth of the business.

The PFIC opportunity has been the really unique one for those who follow the story. I think you can think about PFIC as almost having two separate entities. One is an infant or pediatric onset version of the disease, the classical PFIC, about 500 addressable patients in the U.S. there, so squarely ultra-rare. LIVMARLI has done very well in that setting, and that is, I think, a pretty well-developed market. What is really new and what is kind of driven the inflection in those revenue growth curves that I showed you is this later onset or adult onset PFIC entity. We had a suspicion and collaborated with KOLs and academics that many of the patients who are in adult liver providers' hands today, who are labeled as unexplained cholestasis or idiopathic cholestasis, that they may in fact have a PFIC gene involved in their disease.

This is the effort that the Mirum team has been doing on the patient finding front over the last couple years of kind of going out to adult liver providers, educating them about this literature that some of these patients may in fact have PFIC. We can support genetic testing, which removes that barrier, and ultimately, that has resulted in finding a good number of adult PFIC patients. There are probably about 2,000, we estimate, addressable adult PFIC patients in the United States. Interestingly, I think 10% or less of those are diagnosed today, and that is approximately the penetration here as well. This has been a big part of the growth of the brand, but imagine that we can continue to go much further than 10% in terms of reaching these later onset PFIC patients.

As you pivot to the EXPAND study, we recently announced the top line phase III data here. Positive study, really excited about the effects we saw there on pruritus, as well as bile acids. Quite frankly, the results look pretty comparable to the pivotal phase III study in PFIC. So, really excited about those data. Planning on submitting an sNDA in the first half of next year. The study was an interesting design. It enrolled about half the patients had biliary atresia, cholestatic pruritus associated with biliary atresia, and then the other half were essentially a basket study, a long tail of ultra-rare underlying etiologies that lead to the final common pathway of high bile acids, cholestasis, pruritus, fatigue, et cetera. That is the other half.

About half the study was biliary atresia, and if you just focus on that half from a market opportunity perspective, biliary atresia pruritus, we believe, can be at least as big as Alagille syndrome. About 1,000 addressable patients in the U.S. You will note that is about the same number of addressable patients as we have in Alagille syndrome. It is a bit higher of a dose, worth mentioning, in biliary atresia, and then no competition in biliary atresia. The competitive program failed here. Excited about adding this to our label. This probably comes online more in 2028, but just exciting continued growth prospects for this brand, 2027, 2028, and beyond. Pivoting to the adult IBAT inhibitor, volixibat, same mechanism of action as LIVMARLI. This product is focused in adult rare cholestatic liver diseases, although you will note from the numbers on the page, more common diseases.

Instead of talking about addressable populations of 1,000, 2,000 in the U.S. per indication, here you are talking about 20,000 addressable pruritic PSC patients, 50,000 addressable pruritic PBC patients. Much, much larger opportunities. Obviously, the product will have a different price point than LIVMARLI. We show the clinical data here on this page. The VISTAS data were reported at the EASL meeting in Barcelona earlier this year, the pivotal phase IIb data, really nice effect size, no approved therapies in PSC. Has the potential to be the first approved therapy for this population. In PBC, we have the interim data from VANTAGE shown here, a robust effect size, 2.4 placebo-adjusted delta in pruritus. I think compares very favorably to the landscape of options.

It is a busier field from a competitive standpoint, but feel that robust effect size here positions volixibat well to play a role in the PBC space as well. The final pivotal data from the VANTAGE study is expected in the first quarter of next year. An early pivotal data catalyst coming up next year as well. Now pivoting to the other program in our rare liver disease portfolio, brelovitug. This is a program that came in through an acquisition, which is, as I mentioned at the outset, a key part of Mirum's strategy doing business development. Closed the acquisition of Bluejay Therapeutics closer to the beginning of 2026. For those that are not familiar with hepatitis delta, this is a rare viral infection.

Depending on the country you are in, between 3%-10% of people who have chronic hepatitis B are also co-infected with delta. Unfortunately, the outcomes for patients with hepatitis delta are quite dire. You will see CME programming from experts saying the D is for deadly. Unfortunately, patients have a much higher risk of portal hypertension, liver decompensation, hepatocellular cancer, and death by literature, probably three times higher risk of those things happening than if you have hep B alone. An unmet need, but a rare disease within a common one. We are really excited both about the market opportunity here as well as the product profile of brelovitug. We reported in the second half of this year positive phase III data from both of the pivotal studies, AZURE-1 and AZURE-4.

These were 24-week endpoints focused on the licensing endpoint that FDA wants to see, which is a two-log reduction in viral load and a normalization in liver inflammation as measured by normal ALT levels. This is the regulatory endpoint that is reasonably likely to predict clinical benefit for accelerated approval. So reported those results were positive, and we're heading towards BLA submission. What I'm showing you on the page here is from a presentation at AASLD about a week ago, looking at a cohort of cirrhotic patients who were on brelovitug long term, up to 108 weeks.

What you see here, which is, I think, more reflective than the licensing studies that are focused on 24-week endpoints, at 108 weeks, which is reflective of how patients will use this medicine in the real world, is that you can achieve 100% virologic response, nearly three-quarters of patients achieving target not detected. So very robust antiviral efficacy. It doesn't come with a trade-off on ALT. So you can actually get 100% of patients to normalize their ALT values in this cohort. So I think it creates a really unique positioning for the product. Then on the commercial opportunity side, I think these are the kinds of opportunities where Mirum shines. This is an undeveloped market in the U.S. It's interestingly more developed in European countries and other countries because of Hepcludex from Gilead's earlier approval. But in the U.S., completely undeveloped market.

About 15,000 patients who are diagnosed, insured, and under care today, but many more than that. We estimate 40,000 prevalence. Others, sponsors think it might be higher. The truth is nobody knows the actual prevalence because there just hasn't been enough testing in the U.S. of people who have hepatitis delta, or sorry, who have hepatitis B for delta. In fact, probably less than 10% of patients have ever had a test for delta. So this is really the wood we have to chop and the work we can do to make a big impact for patients and the kind of economics of this business of finding and diagnosing these hepatitis delta patients. I think the European countries show what's possible.

When Hepcludex became available in Europe several years ago, it went from risk-based testing for delta to universal screening, make sure all your hep B patients get tested once, and they found a lot more patients. So I think excited about the years ahead and the market development effort here. Pivoting to the rare genetic disease business, these products, CTEXLI and CHOLBAM, were acquired a couple years ago from a different sponsor. We're really proud of these products at Mirum. As you can see by the numbers on the page, they're not our largest product or largest potential, but I think it shows what a dedicated rare disease company that's focused on patient finding can do. So these products have been around for a while.

When we acquired them, no new data, nothing dramatically changing in the product profiles, but put them in the hands of a team at Mirum who were laser-focused on patient finding. The result, you can see here, is more than doubling the sales. For years, these products were sitting in the low $20 million quarterly sales, and the most recent quarter that Mirum reported, $52 million. How did we double the sales of a very mature business? Patient finding. I have a link of a couple patients who you can actually listen to their testimonial on our website. Unfortunately, patients with diseases like CTX have a long diagnostic odyssey, and unfortunately, the average age of diagnosis is in the 30s. These two sisters were fortunate enough to be diagnosed in their teenage years, but went years with refractory diarrhea, ataxia, cognitive dysfunction, and impairment.

If you can make the diagnosis of CTX, which is hard because most of the symptoms are low acuity, but if you can make the diagnosis, CTEXLI is a transformative medicine. You're talking about a couple hundred patients on each one of these products, but a big impact for patients, and we think a good illustration of what's possible with a focused rare disease company. Then finally, ATEBRIOZ. This is the latest product, also recently licensed by our business development team at Mirum from Incyte Pharmaceuticals. A really fantastic medicine that is designed for the actual cause of this disease. FOP, or Fibrodysplasia Ossificans Progressiva, if you're not familiar, is an ultra-rare bone disorder, and these patients have an activating mutation in ALK2, and that causes hyperactivity in the BMP pathway.

Unfortunately, when these patients have a, what would be for the rest of us, a minor insult to soft tissue or muscle, that can ossify and turn into bone. It's a horrific condition. Essentially, the patients have a second skeleton that forms. By the time you're a teenager, in most cases, you're in a wheelchair, and there's a substantial early mortality impact. The prior sponsors did a great job, I think, designing a product that goes right at the disease. It's a kinase inhibitor that addresses the ALK2 activating mutation. It's an oral small molecule drug, so it can be pretty straightforward from an administration standpoint. You can see the data here that was the basis of the FDA approval, where in the placebo arm, the volume of bone increases in only 24 weeks. In the active, it's stable or perhaps even declining.

Patients cross over to active after 24 weeks, and it continues to recapture the decline trajectory. I think an exciting medicine, ultra-rare condition, about 300 patients diagnosed in the U.S., about 1,000 worldwide, but a very active patient population. We believe this can be at least $200 million in peak sales. Excuse me. The U.S. launch commenced in October, and the EMA review is underway. We're thinking about additional geographic expansion as well. Finally, just to kind of reiterate, feel like we're really well-positioned to execute our strategy at Mirum. Clear line of sight to our guidance of $715 million-$720 million, cash flow positive in 2027, returning to cash flow positive, a strong cash balance. As you can see, in 2026, had a great year of data readouts, new product acquisitions.

In 2027, we like to joke at the company, our regulatory team's not going to be allowed to take any PTO because we're submitting, as you can see, a lot of NDAs and BLAs that'll tee up approvals, potential approvals at the end of 2027 and launches late 2027 and 2028. With that, I'll close my presentation, open up to any questions. Yeah.

Speaker 2

Just a quick one. Can you leverage the relatively new products across your existing promotional infrastructure, or do you need to invest more in?

Peter Radovich
President and COO, Mirum

Thanks for the question. Yeah, the nice thing about the rare genetic business unit and the team that's promoting CTEXLI and CHOLBAM, we did work to look at for ATEBRIOZ, who are the prescribers for ATEBRIOZ? Who are the physicians that take care of patients with FOP? The physicians are different, but the centers are largely the same.

So, we added a couple sales territories, a couple medical people. So I'd say a high degree, short answer is a high degree of leverage from the current business to launch ATEBRIOZ. Thanks for the question. Yep.

Speaker 2

Can you talk about your approach to BD going forward?

Peter Radovich
President and COO, Mirum

Yeah, thanks for the question. Yeah, business development since the company was founded is a core part of the ethos of the company. In fact, LIVMARLI, the company was founded as a really a spin-out transaction from Shire Takeda. Have a fantastic BD team who's very active at this meeting. And we look for clinical stage and later, as you can see by the kind of transactions we've done, whether it be ATEBRIOZ, which was near commercial, Bluejay, brelovitug, which was kind of beginning of phase III, and we'll even look at pre-POC clinical stage opportunities.

Of course, we look in our therapeutic areas of interest, but we think about rare disease more broadly as a therapeutic area. The set of know-how one needs to develop and get regulatory approvals, commercialize, find patients, get market access, and pricing reimbursement at rare and ultra-rare price points. We think of that as a capability and know-how that we can leverage. So we look for broadly in rare disease, often looking at underappreciated programs, asking ourselves, "Are we the right owners?" So we're very active, but I would say we're very happy with our base business. So the bar is high to transact for us, and certainly have a busy schedule ahead of us the next several years. Great. Well, thanks for your interest. Hope you have a great conference.